Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530477 · ClinicalTrials.gov registry record · NA
DXA Precision and Accuracy Comparison Study
A NA study, sponsored by GE Healthcare.
- Terminated
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT01530477: Clinical Trial NA study, sponsored by GE Healthcare.
NCT01530477 is a NA study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01530477, a NA study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
This study is being conducted to examine the performance of three common DXA machines (1) Lunar iDXA, (2) Lunar Prodigy and (3) Hologic Discovery A in measuring bone density and body fat.
Primary Outcome
BMD precision will be reported across three DXA devices in major skeletal and body composition sites. The short-term precision was calculated as RMS-SD (root mean square standard deviation) over the mean for each cohort. The skeletal cohort will not have short-term precision value for body composition indexes due to the different region of measurement. The same will apply to the body composition cohort. As the result, the "Skeletal \& Body Composition" cohort identified in participant flow and o
Interventions
- DEVICE Lunar Prodigy (GEHC)
- DEVICE Lunar iDXA (GEHC)
- DEVICE Discovery A (Hologic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-12 |
| Phase | NA |
Why NCT01530477 stopped before completion
NCT01530477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Lunar Prodigy (GEHC) is the first listed.
NCT01530477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01530477 about?
NCT01530477 is a clinical study titled "DXA Precision and Accuracy Comparison Study". This study is being conducted to examine the performance of three common DXA machines (1) Lunar iDXA, (2) Lunar Prodigy and (3) Hologic Discovery A in measuring bone density and body fat.
What is the current status of trial NCT01530477?
This trial is currently terminated. It is a NA study. The enrollment target is 82 participants. The study started on 2012-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01530477?
The interventions under investigation include: Lunar Prodigy (GEHC) (DEVICE), Lunar iDXA (GEHC) (DEVICE), Discovery A (Hologic (DEVICE).
Who is sponsoring clinical trial NCT01530477?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01530477's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia